Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577630 | 0.81 | KDM4E (0.30) | — | |
| SCHEMBL28664583 | 0.77 | DYRK1A (0.38) | DYRK1APDE4D | |
| SCHEMBL2351902 | 0.70 | — | — | |
| SCHEMBL245719 | 0.70 | — | — | |
| SCHEMBL18860621 | 0.69 | — | — | |
| SCHEMBL338850 | 0.69 | KDM4E (0.33) | — | |
| SCHEMBL8533 | 0.68 | ADORA2A (0.33) | — | |
| SCHEMBL13086232 | 0.68 | DYRK1A (0.33) | DYRK1APDE4D | |
| Hydrochloric Acid SCHEMBL29954786 | 0.68 | DYRK1A (0.44) | DYRK1APDE4D | |
| SCHEMBL18706311 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637430-B2 | Interleukin-17 (IL-17) inhibitors | HITGEN INC. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4177249-B1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4628489-A1 | 7-AZAINDOLE COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | Fudan University (CN) | 2025-10-08 | — | — | EP | disclosed |
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024179529-A1 | SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| US-20240190860-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| WO-2024114661-A1 | 7-AZAINDOLE COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 复旦大学 | 2024-06-06 | — | — | WO | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010065383-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2142511-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| EP-2078003-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008054702-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637430-B2 | Interleukin-17 (IL-17) inhibitors | IL17A, IL2, IL23R | DYRK1A 4350/4885PDE4D 3961/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | DYRK1A 1535/4885PDE4D 1014/4885 |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | DYRK1A 457/4885PDE4D 1561/4885 |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | SMG1, RACK1, TIA1 | DYRK1A 2462/4885PDE4D 3547/4885 |
| US-20240190860-A1 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR5, LPAR1 | DYRK1A 1980/4885PDE4D 313/4885 |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HNMT, NNT, NQO1 | DYRK1A 3960/4885PDE4D 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.